speb/financial-data huggingface dataset:
ASML.TO income_statement (quarterly, 2025-09-30) — Total Other Finance Cost: -19400000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Working Capital: 5921400000.00
ASML.TO income_statement (annual, 2025-12-31) — +Operating Expense: 5956600000.00
ASML.TO income_statement (quarterly, 2025-12-31) — +Operating Expense: 1637500000.00
ASML.TO income_statement (annual, 2025-12-31) — +Total Revenue: 32667300000.00
ASML.TO income_statement (quarterly, 2025-12-31) — +Total Revenue: 9718100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Accounts Payable: 3521800000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 3521800000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Accounts Receivable: 3023000000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 3023000000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -4926500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -4926500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 4107100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 4107100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: 0.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: 0.00
ASML.TO cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 49700000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 28000000.00
ASML.TO income_statement (annual, 2025-12-31) — Basic Average Shares: 17652094261.00
ASML.TO income_statement (quarterly, 2025-12-31) — Basic Average Shares: 17561221189.00
ASML.TO income_statement (annual, 2025-12-31) — Basic EPS: 0.54
ASML.TO income_statement (quarterly, 2025-12-31) — Basic EPS: 0.16
ASML.TO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 12735900000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 5126500000.00
ASML.TO cash_flow (annual, 2025-12-31) — Capital Expenditure: -1631200000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -470400000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Capital Stock: 34900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 34900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 12916000000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 12916000000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 13321900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 13321900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -2550300000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: -619200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Cash Equivalents: 11780700000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 11780700000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Cash Financial: 1135300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Cash Financial: 1135300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -8670500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -2613300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -3777800000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -1006300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 12658500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 11410300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Account Payable: 13400000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Accrued Expense: -237300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Inventory: -832500000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -561900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 1456500000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Payable: 13400000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -223900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Receivables: 1188300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Change In Working Capital: 1026500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 7640700000.00
ASML.TO cash_flow (annual, 2025-12-31) — Changes In Account Receivables: 1415500000.00
ASML.TO cash_flow (annual, 2025-12-31) — Changes In Cash: 210200000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Changes In Cash: 7790700000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Common Stock: 34900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Common Stock: 34900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Common Stock Dividend Paid: -2550300000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Common Stock Dividend Paid: -619200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Common Stock Equity: 19612200000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 19612200000.00
ASML.TO cash_flow (annual, 2025-12-31) — Common Stock Issuance: 142300000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 32700000.00
ASML.TO cash_flow (annual, 2025-12-31) — Common Stock Payments: -5950000000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -1700000000.00
ASML.TO income_statement (annual, 2025-12-31) — Cost Of Revenue: 15409300000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 4649500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 2567300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 2567300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Current Assets: 30616100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Current Assets: 30616100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Current Debt: 1681900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Current Debt: 1681900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 1681900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 1681900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 16006300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 16006300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 16006300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 16006300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Current Liabilities: 24263900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 24263900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Deferred Income Tax: 180700000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: 118800000.00
ASML.TO cash_flow (annual, 2025-12-31) — Deferred Tax: 180700000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Deferred Tax: 118800000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Defined Pension Benefit: 129900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Defined Pension Benefit: 129900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 1025900000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 255200000.00
ASML.TO cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 1025900000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 255200000.00
ASML.TO income_statement (annual, 2025-12-31) — Diluted Average Shares: 17670268875.00
ASML.TO income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 17583939457.00
ASML.TO income_statement (annual, 2025-12-31) — Diluted EPS: 0.54
ASML.TO income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.16
ASML.TO income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 2839600000.00
ASML.TO income_statement (annual, 2025-12-31) — EBIT: 11524400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — EBIT: 3431100000.00
ASML.TO income_statement (annual, 2025-12-31) — EBITDA: 12550300000.00
ASML.TO income_statement (quarterly, 2025-12-31) — EBITDA: 3686300000.00
ASML.TO income_statement (annual, 2025-12-31) — Earnings From Equity Interest Net Of Tax: 216700000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Earnings From Equity Interest Net Of Tax: 16000000.00
ASML.TO cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: 94600000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: 300900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -30100000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -1200000.00
ASML.TO cash_flow (annual, 2025-12-31) — End Cash Position: 12916000000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — End Cash Position: 12916000000.00
ASML.TO cash_flow (annual, 2025-12-31) — Financing Cash Flow: -8670500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -2613300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Finished Goods: 2135100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Finished Goods: 2135100000.00
ASML.TO cash_flow (annual, 2025-12-31) — Free Cash Flow: 11027300000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 10939900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 135800000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 135800000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Goodwill: 4588600000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Goodwill: 4588600000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 5128700000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 5128700000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 3023000000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 3023000000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Gross PPE: 13161300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Gross PPE: 13161300000.00
ASML.TO income_statement (annual, 2025-12-31) — Gross Profit: 17258000000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Gross Profit: 5068600000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Hedging Assets Current: 33600000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Hedging Assets Current: 33600000.00
ASML.TO cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 1621400000.00
ASML.TO income_statement (annual, 2025-12-31) — Interest Expense: 118300000.00
ASML.TO income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 118300000.00
ASML.TO income_statement (annual, 2025-12-31) — Interest Income: 223000000.00
ASML.TO income_statement (annual, 2025-12-31) — Interest Income Non Operating: 223000000.00
ASML.TO cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 114500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Inventories Adjustments Allowances: -772800000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Inventories Adjustments Allowances: -772800000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Inventory: 11429300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Inventory: 11429300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Invested Capital: 24003100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Invested Capital: 24003100000.00
ASML.TO cash_flow (annual, 2025-12-31) — Investing Cash Flow: -3777800000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -1006300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Investments And Advances: 2143300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 2143300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 142300000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 32700000.00
ASML.TO cash_flow (annual, 2025-12-31) — Issuance Of Debt: 754200000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 739200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Land And Improvements: 6421100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 6421100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Leases: 955200000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Leases: 955200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Loans Receivable: 266100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Loans Receivable: 266100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Long Term Debt: 2709000000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 2709000000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 2709000000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 2709000000.00
ASML.TO cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 754200000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 739200000.00
ASML.TO cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -1066700000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -1066000000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 2143300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 2143300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 5779600000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 5779600000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 1210000000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -5807700000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -1667300000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Income: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Income: 2839600000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 2839600000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 2839600000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 2839600000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 2839600000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 9609400000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 2839600000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 2839600000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -57600000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -22500000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Interest Income: 104700000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Interest Income: 11200000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -1703100000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -496600000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -312500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -326800000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -312500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -326800000.00
ASML.TO income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 104700000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 11200000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net Other Investing Changes: -443500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: -39300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Net PPE: 8234800000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Net PPE: 8234800000.00
ASML.TO cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -1573600000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -447900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 14483500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 14483500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Accounts Receivable: 13300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Accounts Receivable: 13300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Accrued Expenses: 432200000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Accrued Expenses: 432200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 1719400000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 1719400000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 3549300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 3549300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 3366300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 3366300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 1719400000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 1719400000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 183000000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 183000000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Note Receivables: 1653900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Note Receivables: 1653900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Non Current Prepaid Assets: 914500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Non Current Prepaid Assets: 914500000.00
ASML.TO income_statement (annual, 2025-12-31) — Normalized EBITDA: 12550300000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 3686300000.00
ASML.TO income_statement (annual, 2025-12-31) — Normalized Income: 9609400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Normalized Income: 2839600000.00
ASML.TO cash_flow (annual, 2025-12-31) — Operating Cash Flow: 12658500000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 11410300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Operating Gains Losses: 94600000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 300900000.00
ASML.TO income_statement (annual, 2025-12-31) — Operating Income: 11301400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Operating Income: 3431100000.00
ASML.TO income_statement (annual, 2025-12-31) — Operating Revenue: 32667300000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Operating Revenue: 9718100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 385417665.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 385417665.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Current Assets: 350500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 350500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 24263900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 24263900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 135800000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 135800000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 540100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 540100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 12700000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 12700000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Properties: 5400000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Properties: 5400000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Receivables: 1054100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Receivables: 1054100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 405900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 405900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Payables: 4008400000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Payables: 4008400000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 6575700000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 6575700000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Prepaid Assets: 861500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 861500000.00
ASML.TO income_statement (annual, 2025-12-31) — Pretax Income: 11406100000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Pretax Income: 3442300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Properties: 0.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
ASML.TO cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: 469400000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Provisionand Write Offof Assets: 171500000.00
ASML.TO cash_flow (annual, 2025-12-31) — Purchase Of Business: 0.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 1210000000.00
ASML.TO cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -57600000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -22500000.00
ASML.TO cash_flow (annual, 2025-12-31) — Purchase Of Investment: -1708400000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -501900000.00
ASML.TO cash_flow (annual, 2025-12-31) — Purchase Of PPE: -1573600000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -447900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Raw Materials: 5298500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Raw Materials: 5298500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Receivables: 4619300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Receivables: 4619300000.00
ASML.TO income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 15409300000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 4649500000.00
ASML.TO income_statement (annual, 2025-12-31) — Reconciled Depreciation: 1025900000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 255200000.00
ASML.TO cash_flow (annual, 2025-12-31) — Repayment Of Debt: -1066700000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -1066000000.00
ASML.TO cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -5950000000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -1700000000.00
ASML.TO income_statement (annual, 2025-12-31) — Research And Development: 4698800000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Research And Development: 1262300000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Retained Earnings: 17587300000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 17587300000.00
ASML.TO cash_flow (annual, 2025-12-31) — Sale Of Investment: 5300000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 5300000.00
ASML.TO income_statement (annual, 2025-12-31) — Selling General And Administration: 1257800000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Selling General And Administration: 375200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Share Issued: 388147674.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Share Issued: 388147674.00
ASML.TO cash_flow (annual, 2025-12-31) — Stock Based Compensation: 202300000.00
ASML.TO cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 55600000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Stockholders Equity: 19612200000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 19612200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Tangible Book Value: 14483500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 14483500000.00
ASML.TO income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (annual, 2025-12-31) — Tax Provision: 2013400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Tax Provision: 618700000.00
ASML.TO income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.18
ASML.TO income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.18
ASML.TO balance_sheet (annual, 2025-12-31) — Taxes Receivable: 276100000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 276100000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Assets: 50566600000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Assets: 50566600000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Capitalization: 22321200000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 22321200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Debt: 4390900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Debt: 4390900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 19612200000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 19612200000.00
ASML.TO income_statement (annual, 2025-12-31) — Total Expenses: 21365900000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Total Expenses: 6287000000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 30954400000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 30954400000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 19950500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 19950500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 6690500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 6690500000.00
ASML.TO income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 11301400000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 3431100000.00
ASML.TO income_statement (annual, 2025-12-31) — Total Other Finance Cost: -104700000.00
ASML.TO income_statement (quarterly, 2025-12-31) — Total Other Finance Cost: -11200000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Total Tax Payable: 486600000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 486600000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 2730009.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 2730009.00
ASML.TO balance_sheet (annual, 2025-12-31) — Treasury Stock: 2252900000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 2252900000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Work In Process: 4768500000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Work In Process: 4768500000.00
ASML.TO balance_sheet (annual, 2025-12-31) — Working Capital: 6352200000.00
ASML.TO balance_sheet (quarterly, 2025-12-31) — Working Capital: 6352200000.00
ASML.TO income_statement (quarterly, 2026-03-31) — +Operating Expense: 1487200000.00
ASML.TO income_statement (quarterly, 2026-03-31) — +Total Revenue: 8766900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 4402900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 500000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 1322500000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Basic Average Shares: 17511240999.00
ASML.TO income_statement (quarterly, 2026-03-31) — Basic EPS: 0.16
ASML.TO cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 12916000000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -422300000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 7970400000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 8376300000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -617000000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -2274900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -487600000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -2185600000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -5158100000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Changes In Cash: -4948100000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 20829500000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 35000000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -1000000000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 4121900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Current Assets: 27583800000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 20288000000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -42100000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Deferred Tax: -42100000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 259400000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 259400000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 17524871960.00
ASML.TO income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.16
ASML.TO income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 2756700000.00
ASML.TO income_statement (quarterly, 2026-03-31) — EBIT: 3157800000.00
ASML.TO income_statement (quarterly, 2026-03-31) — EBITDA: 3157800000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest Net Of Tax: 104600000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: -113300000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 2500000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — End Cash Position: 7970400000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -2274900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -2607900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Goodwill: 4588600000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 5120700000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Gross PPE: 8090700000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Gross Profit: 4645000000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Inventory: 11711200000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Invested Capital: 2705600000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -487600000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 1322500000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 2258400000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 35000000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Loans Receivable: 267800000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 2705600000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 2705600000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -692900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 935900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -965000000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Income: 2756700000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 2756700000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 2756700000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2756700000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2756700000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 2756700000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 2756700000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: -19900000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Interest Income: 40900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -1800000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -692900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -692900000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 40900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: -63500000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Net PPE: 8090700000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -402400000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 15708800000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Accounts Receivable: 198200000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Accrued Expenses: 416300000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 1761900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 3821100000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 3585700000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 1761900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 235400000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Non Current Note Receivables: 1725900000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 3157800000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Normalized Income: 2756700000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -2185600000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -113300000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Operating Income: 3157800000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Operating Revenue: 8766900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 385417665.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 1586300000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 20288000000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 532100000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 1320900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Other Properties: 8090700000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Other Receivables: 1174100000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 405900000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Pretax Income: 3198700000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Provisionand Write Offof Assets: 80200000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: -19900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -1800000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -402400000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Receivables: 5910000000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 4121900000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 259400000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -692900000.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -1000000000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Research And Development: 1184900000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Selling General And Administration: 302300000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Share Issued: 385417665.00
ASML.TO cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 31100000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 20829500000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 15708800000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (quarterly, 2026-03-31) — Tax Provision: 546600000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.17
ASML.TO balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 65200000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Total Assets: 48060500000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 23535100000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Total Debt: 2705600000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 20829500000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Total Expenses: 5609100000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 27231000000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 20476700000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 6943000000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 3157800000.00
ASML.TO income_statement (quarterly, 2026-03-31) — Total Other Finance Cost: -40900000.00
ASML.TO balance_sheet (quarterly, 2026-03-31) — Working Capital: 7295800000.00
ASML.TO income_statement (quarterly, 2026-06-30) — +Operating Expense: 1579300000.00
ASML.TO income_statement (quarterly, 2026-06-30) — +Total Revenue: 9326500000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Accounts Receivable: 7252600000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Available For Sale Securities: 1324900000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Basic Average Shares: 17470348117.00
ASML.TO income_statement (quarterly, 2026-06-30) — Basic EPS: 0.17
ASML.TO balance_sheet (quarterly, 2026-06-30) — Cash And Cash Equivalents: 6671900000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Cash Cash Equivalents And Short Term Investments: 7581500000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Common Stock Equity: 21825400000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Cost Of Revenue: 4291100000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Current Assets: 29549200000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Current Liabilities: 22154600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Diluted Average Shares: 17488522731.00
ASML.TO income_statement (quarterly, 2026-06-30) — Diluted EPS: 0.17
ASML.TO income_statement (quarterly, 2026-06-30) — Diluted NI Availto Com Stockholders: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — EBIT: 3456100000.00
ASML.TO income_statement (quarterly, 2026-06-30) — EBITDA: 3456100000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Earnings From Equity Interest Net Of Tax: 41100000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Goodwill: 4588600000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Goodwill And Other Intangible Assets: 5178100000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Gross PPE: 8135000000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Gross Profit: 5035400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Inventory: 11739500000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Invested Capital: 1984400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Investmentin Financial Assets: 1324900000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Investments And Advances: 2310700000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Loans Receivable: 269200000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Long Term Debt: 1984400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Long Term Debt And Capital Lease Obligation: 1984400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Long Term Equity Investment: 985800000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Income: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Income Common Stockholders: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Income Continuous Operations: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Income From Continuing And Discontinued Operation: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Income From Continuing Operation Net Minority Interest: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Income Including Noncontrolling Interests: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Interest Income: 30000000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Net Non Operating Interest Income Expense: 30000000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Net PPE: 8135000000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Net Tangible Assets: 16647300000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Non Current Accrued Expenses: 440000000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Non Current Deferred Assets: 1742700000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Non Current Deferred Liabilities: 3810400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Non Current Deferred Revenue: 3570300000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Non Current Deferred Taxes Assets: 1742700000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Non Current Deferred Taxes Liabilities: 240100000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Non Current Note Receivables: 1766800000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Normalized EBITDA: 3456100000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Normalized Income: 2917600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Operating Income: 3456100000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Operating Revenue: 9326500000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Ordinary Shares Number: 384100000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Other Current Assets: 1570300000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Other Current Liabilities: 22154600000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Other Intangible Assets: 589500000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Other Non Current Assets: 1532300000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Other Properties: 8135000000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Other Receivables: 1052000000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Other Short Term Investments: 909600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Pretax Income: 3486100000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Receivables: 8657900000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Reconciled Cost Of Revenue: 4291100000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Research And Development: 1276600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Selling General And Administration: 302700000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Share Issued: 386830009.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Stockholders Equity: 21825400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Tangible Book Value: 16647300000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (quarterly, 2026-06-30) — Tax Provision: 609600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Tax Rate For Calcs: 0.17
ASML.TO balance_sheet (quarterly, 2026-06-30) — Taxes Receivable: 84100000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Total Assets: 50214800000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Total Capitalization: 23809800000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Total Debt: 1984400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Total Equity Gross Minority Interest: 21825400000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Total Expenses: 5870400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Total Liabilities Net Minority Interest: 28389400000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Total Non Current Assets: 20665600000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Total Operating Income As Reported: 3456100000.00
ASML.TO income_statement (quarterly, 2026-06-30) — Total Other Finance Cost: -30000000.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Treasury Shares Number: 2730009.00
ASML.TO balance_sheet (quarterly, 2026-06-30) — Working Capital: 7394600000.00
ASMS.NS income_statement (annual, 2022-03-31) — +Operating Expense: 542322000.00
ASMS.NS income_statement (annual, 2022-03-31) — +Total Revenue: 655618000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Accounts Payable: 1985225000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Accounts Receivable: 10849321000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -1791621000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 1770399000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -928680000.00
ASMS.NS income_statement (annual, 2022-03-31) — Amortization: 20000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 20000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Available For Sale Securities: 1374302000.00
ASMS.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 34048861.00
ASMS.NS income_statement (annual, 2022-03-31) — Basic EPS: -14.77
ASMS.NS cash_flow (annual, 2022-03-31) — Beginning Cash Position: 112138000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 31718000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Capital Expenditure: -57000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Capital Stock: 340489000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 29000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Short Term Investments: 90702000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 29000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Change In Inventory: -12044000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: 36503000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Change In Receivables: -41141000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Change In Working Capital: -16605000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Changes In Cash: 41135000.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Common Stock: 340489000.00
ASMS.NS cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: 0.00
ASMS.NS balance_sheet (annual, 2022-03-31) — Common Stock Equity: 664687000.00